UNSPSC 51202410: Muromonab cd3

This classification denotes a monoclonal antibody and immunosuppressant with the molecular formula C6460H9946N1720O2043S56, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JGA39ICE2V, more generally known as muromonab cd3. European Medicines Agency schedules muromonab cd3 in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03355MIG. The term MUROMONAB CD3 is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 3, no. 3, 1989, list 29. SMILES: NONE.

UNSPSC 51202410 Muromonab cd3, a Commodity code, does not align with the recent state and local procurement activity tagged under it. The code nominally describes a monoclonal antibody immunosuppressant used in transplant medicine, yet the recent solicitations in the data block reflect purchases of naloxone, emergency medical supplies, generic pharmaceuticals and over-the-counter products, and direct-to-manufacturer pharmacy programs—none of which match the code's clinical scope. The mismatch suggests either a data-tagging error or that state and local agencies are using this code as a catch-all for pharmaceutical and medical-supply procurement outside its intended narrow product class.

The recent opportunities instead show state and local governments acquiring broad pharmaceutical and emergency-response supplies through multiple issuing bodies: Seminole County, Florida (naloxone and drug deactivation systems via IFB); the City of Tampa (medical and first aid supplies for fire rescue via IFB with an estimated contract value of $700,000.00 and a Small Local Business Enterprise set-aside); the Minnesota Multistate Cooperative Purchasing Alliance (generic multi-source pharmaceuticals and OTC products via RFP, response due March 26, 2026); and the Texas Health and Human Services Commission (direct-to-manufacturer pharmacy program capabilities via RFI, response due April 3, 2026). Geographic activity spans Florida, Texas, Minnesota, and Oregon. The code shows little relevant recent activity under its nominal scope; vendors seeking muromonab cd3 procurement should verify with issuing bodies whether their actual needs align with this code or whether a different pharmaceutical or immunosuppressant code better reflects their buying intent.